The AI in Drug Discovery Market is Set to Reach $17.56 Billion by 2031

AI in Drug Discovery Market Growth

According to the recent report by MarketsandMarkets™, the AI in drug discovery sector is on an impressive upward trajectory. The market, which is currently valued at approximately $5.09 billion, is anticipated to soar to an astounding $17.56 billion by 2031. This exponential growth, signifying a compound annual growth rate (CAGR) of 28.1% from 2026 to 2031, underscores the transformative potential of artificial intelligence within the pharmaceutical domain.

Market Trends

The AI in drug discovery landscape is evolving distinctly from fragmented, stage-specific applications to robust, cohesive ecosystems that seamlessly integrate various components of the discovery process. Organizations are increasingly leveraging AI platforms to enhance decision-making throughout the drug development pipeline, which facilitates quicker prioritization of potential drug candidates and more strategic portfolio management. This shift indicates a move away from standalone AI solutions toward expansive, enterprise-level discovery platforms, reshaping technology investments and establishing AI as a crucial driving force for future pharmaceutical innovations.

As of 2025, North America held a dominant share of the market, comprising about 44.9%. Oncology emerged as the leading therapeutic area, accounting for 38.6% of the market share within that same year. Additionally, cloud-based deployment models are predicted to grow at a staggering CAGR of 28.7% during the forecast period.

Commercialization Phase

The AI in drug discovery market is entering a new commercialization phase, whereby pharmaceutical and biotechnology companies are keen on integrating AI throughout the entire drug discovery continuum rather than confining its use to isolated research tasks. This advanced integration of multimodal AI, comprehensive foundation models, and sophisticated computational biology platforms enables targeted identification, optimization of molecular designs, and improved candidate selection—all with enhanced precision. The surge in availability of multi-omics datasets, increasing investments in precision medicine, and the drive for more efficient R&D productivity are converging to create lucrative opportunities for AI platform providers and tech developers involved in life sciences.

As companies focus on expedited and cost-effective drug development, the demand for scalable AI-driven discovery platforms is expected to experience substantial growth throughout the forecast timeline.

Competitive Landscape

The competitive atmosphere is swiftly evolving with the advent of autonomous scientific workflows and AI-empowered laboratory automation. Instead of channeling funds into isolated AI applications, pharmaceutical firms are adopting integrated platforms that marry high-performance computing with generative AI, molecular simulations, and data management workflows to enhance the drug discovery process. Noteworthy strategic collaborations are becoming apparent, such as the deal between NVIDIA and Eli Lilly to form a co-innovation AI lab aimed at developing next-generation foundation models for biology and chemistry.

This partnership, with a remarkable investment plan of up to $1 billion over five years, signifies the critical importance of AI frameworks, proprietary models, and consolidated discovery platforms in achieving competitive differentiation as companies transition towards AI-integrated research environments.

De Novo Drug Design

In terms of market shares, the de novo drug design segment was the largest in 2025. The significant rise in the adoption of generative AI and deep learning techniques has dramatically enhanced the capacity to innovate unique molecular structures with desired biological properties. AI-driven de novo design empowers researchers to expeditiously create, screen, and refine potential drug candidates while minimizing dependence on traditional methodologies, thus accelerating early-stage research and enhancing the quality of candidate selection. This methodology is expected to maintain its significance as AI technologies improve access to larger and more diverse datasets in biology and chemistry.

The cloud-based segment is projected to achieve notable CAGR growth from 2026 through 2031, driven by the growing computational demands of AI applications, the extensive use of vast biological datasets, and the necessity for scalable infrastructure to support joint drug discovery efforts. Partnerships between AI solution providers and cloud service firms are enabling companies to deploy advanced capabilities without the burden of excessive investments in on-premises infrastructure.

Regional Outlook

Among various regions, the Asia Pacific area is expected to exhibit the highest growth rate in the AI in drug discovery market over the analysis period. This upsurge is fueled by the increasing investments in pharmaceutical R&D, a burgeoning biotechnology sector, and strong governmental backing for AI and life science advancements. Nations like China, Japan, South Korea, Singapore, and India are reinforcing their AI research initiatives through national strategies and collaborative ventures in biomedical research. The proliferation of partnerships across pharmaceutical firms, AI tech vendors, and academic institutions is further catalyzing the adoption of AI-enhanced drug discovery solutions, positioning Asia Pacific as the fastest-growing market regionally.

Key Players

Noteworthy players in the AI in Drug Discovery landscape include NVIDIA Corporation, Schrödinger, Recursion, Insilico Medicine, Google, Microsoft Corporation, Tempus AI, Illumina, XtalPi, and Iktos. These entities are at the forefront, driving innovation and shaping the future trajectory of AI applications in drug discovery.